RADNOSTIX INC 8-K

What Happened

• Radnostix, Inc. (formerly International Isotopes, Inc.) filed an 8‑K on March 16, 2026 reporting two material events. On March 11, 2026 the company and buyer American Fuel Resources, LLC (AFR) mutually terminated the Asset Purchase Agreement (APA) dated February 8, 2024 to sell the company’s depleted uranium deconversion and fluorine extraction plant (the “DUF6 Plant”). AFR had made a $50,000 non‑refundable prepayment plus $120,000 in non‑refundable NRC extension fees but was unable to pay the remaining $12,450,000 by the March 31, 2026 outside date; the parties withdrew the pending NRC license transfer application and ended the deal.
• Separately, following an internal audit on February 19, 2026 Radnostix initiated a voluntary recall (with FDA knowledge) of certain lots of its dibasic sodium phosphate capsules shipped August 19, 2024–February 17, 2026 because some lots may be out of specification for final capsule weight. The company says its Generic Sodium Iodide I‑131 product was not impacted.

Key Details

• APA termination: February 8, 2024 APA ended by mutual consent on March 11, 2026; AFR had paid $170,000 in non‑refundable fees total ($50,000 + $120,000) and would have paid $12,450,000 at closing.
• NRC transfer: Parties were in the final stages of U.S. Nuclear Regulatory Commission consent to transfer the NRC license but withdrew the application.
• Recall costs (estimated): one‑time ~$75,000 charge to Q4 2025 (inventory write‑off) and ~$50,000 charge to Q1 2026 (customer refunds); expected additional 2026 costs of ~ $75,000 (new capsule inventory) and $25,000–$75,000 per week in lost revenue; company expects impacts to not extend beyond Q2 2026.
• Operational note: Radnostix will regain control of the DUF6 Plant assets and will evaluate options for those assets going forward.

Why It Matters

• Termination of the APA means Radnostix will not receive the previously anticipated $12.45M sale proceeds, will not record any gain from that sale, and will not use proceeds to repay long‑term notes or support previously described cash/asset/liability changes—facts the company says reverse assumptions it disclosed in prior filings. Regaining the DUF6 Plant assets could preserve future value but also means the company retains related operational and regulatory responsibilities.
• The voluntary capsule recall is expected to produce modest, near‑term charges and some lost revenue but, per the company, should not materially disrupt supply of its Generic Sodium Iodide I‑131 product. Investors should monitor upcoming quarterly filings for updated financial impacts and management plans for the DUF6 Plant and recall remediation.